Candida vaginitis in non-pregnant patients: A study of antifungal susceptibility testing and virulence factors

Journal of Obstetrics and Gynaecology

Volumn 33, Issue 4, 2013, Pages 378-383

  Kalkanci, A ^a   Guzel A B ^b   Jabban, I I K ^a   Aydin, M ^a   Ilkit, M ^b   Kustimur S ^a  

^a GAZI UNIVERSITY   (Turkey)

^b CUKUROVA UNIVERSITY   (Turkey)

Author keywords

Antifungal susceptibility; Candida albicans; Fluconazole; Germ tube; Proteinase

Indexed keywords

AMPHOTERICIN B; BORIC ACID; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; NYSTATIN; VIRULENCE FACTOR;

ADULT; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASYMPTOMATIC DISEASE; BACTERIUM CARRIER; CANDIDA; CANDIDA GLABRATA; CONTROLLED STUDY; FEMALE; FUNGAL VIRULENCE; FUNGUS CULTURE; FUNGUS ISOLATION; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RECURRENT VULVOVAGINAL CANDIDOSIS; VAGINA CANDIDIASIS; VULVOVAGINAL CANDIDOSIS;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, VULVOVAGINAL; CASE-CONTROL STUDIES; FEMALE; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RECURRENCE; VIRULENCE FACTORS; YOUNG ADULT;

EID: 84877310268     PISSN: 01443615     EISSN: 13646893     Source Type: Journal    
DOI: 10.3109/01443615.2013.767323     Document Type: Article

References (29)

1. Biasoli MS, Tosello ME, Luque AG , Magar ó HM . 2010. Adherence, colonization and dissemination of Candida dubliniensis and other Candida species. Medical Mycology 48: 291-297.
2. Boriollo MF , Bassi RC , dos Santos Nascimento CM , Feliciano LM , Francisco SB , Barros LM , et al . 2009 . Distribution and hydrolytic enzyme characteristics of Candida albicans strains isolated from diabetic patients and their non-diabetic consorts . Oral Microbiology and Immunology 24 : 437-450 .
3. Chong PP , Abdul Hadi SR , Lee YL, Phan CL, Tan BC , Ng KP , et al. 2007. Genotyping and drug resistance profi le of Candida spp. in recurrent and one-off vaginitis, and high association of non-albicans species with nonpregnant status. Infection, Genetics and Evolution 7: 449-456.
4. Clinical Laboratory Standards Institution . Reference method for broth dilution antifungal susceptibility testing of yeasts . Approved standard CLSI document M27-A3. Wayne, PA, 2008 .
5. Costa CR , Passos XS, e Souza LKH, Lucena Pde A, Fernandes Ode F , Silva Mdo R , et al. 2010. Diff erences in exoenzyme production and adherence ability of Candida spp . isolates from catheter, blood and oral cavity. Revista do Instituto de Medicina Tropical de Sao Paulo 52 : 139-143 .
6. das Neves J , Pinto E , Teixeira B , Dias G , Rocha P , Cunha T , et al . 2008 . Local treatment of vulvovaginal candidosis: general and practical considerations . Drugs 68 : 1787-1802 .
7. Fan SR , Liu XP . 2011 . In vitro fl uconazole and nystatin susceptibility and clinical outcome in complicated vulvovaginal candidosis . Mycoses 54 : 501-505 .
8. Ferrer J . 2000. Vaginal candidosis: epidemiological and etiological factors. International Journal of Gynecology and Obstetrics 71: s21-s27.
9. Galá n-Ladero A, Blanco MT , Sacrist á n B , Fern á ndez-Calder ó n MC, P eŕrez-Giraldo C , G ó mez-Garcia AC . 2010 . Enzymatic activities of Candida tropicalis isolated from hospitalized patients. Medical Mycology 48: 207-210.
10. Gurcan S , Alver O , Ercan I , Ener B . 2010 . Evaluation of virulence in various Candida species: in vitro and in vivo study . Turkish Journal of Medical Sciences 30: 1493-1502.
11. Guzel AB , Ilkit M , Akar T , Burgut R , Demir SC . 2011 . Evaluation of risk factors in patients with vulvovaginal candidiasis and the value of chromID Candida agar versus CHROMagar Candida for recovery and presumptive identifi cation of vaginal yeast species. Medical Mycology 49: 16-25.
12. Ilkit M , Guzel AB . 2011 . The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidosis: A mycological perspective . Critical Reviews in Microbiology 37: 250-261.
13. Kalkanci A, Bozdayi G, Biri A, Kustimur S . 2005. Distribution of secreted aspartyl proteinases using a polymerase chain reaction assay with SAP specifi c primers in Candida albicans isolates . Folia Microbiologica 50 : 409-413 .
14. Lian CH , Liu WD . 2007 . Diff erential expression of Candida albicans secreted aspartyl proteinase in human vulvovaginal candidiasis. Mycoses 50: 383-390 .
15. Luo G, Samaranayake LP , Yau JY . 2001. Candida species exhibit diff erential in vitro hemolytic activities . Journal of Clinical Microbiology 39 : 2971-2974 .
16. Pfaller MA , Andes D , Diekema DJ , Espinell-Ingroff A, Sheehan D; CLSI Subcommittee for Antifungal Susceptibility Testing . 2010 . Wild-type MIC distributions, epidemiological cutoff values and species-specifi c clinical breakpoints for fl uconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods . Drug Resistance Updates 13 : 180-195 .
17. Price MF , Wilkinson ID , Gentry LO . 1982 . Plate method for detection of phospholipase activity in Candida albicans . Sabouradia 20 : 7-14 .
18. Ray D , Goswami R , Banarjee U , Dadhal V , Goswami D , Mandal P , et al. 2007. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fl uconazole in patients with diabetes and vulvovaginal candidiasis. Diabetes Care 30: 312-317.
19. Richter SS, Galask RP , Messer SA, Hollis RJ , Diekema DJ , Pfaller MA . 2005. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases . Journal of Clinical Microbiology 43 : 2155-2162 .
20. R üchel R , B ö ning B , Borg M . 1986. Characterization of a secretory proteinase of Candida parapsilosis and evidence for the absence of the enzyme during infection in vitro . Infection and Immunity 53: 411-419.
21. Sacrist á n B , Blanco MT , Galá n-Ladero A, Blanco J , P eŕrez-Giraldo C, G ó mez-Garc í a AC . 2011 . Aspartyl proteinase, phospholipase, hemolytic activities and biofi lm production of Candida albicans isolated from bronchial aspirates of ICU patients. Medical Mycology 49: 94-97.
22. Seider K, Heyken A, L ü ttich A, Miramó n P , Hube B . 2010. Interaction of pathogenic yeasts with phagocytes: survival, persistence and escape . Current Opinion in Microbiology 13: 392-400.
23. Sobel JD . 2007. Vulvovaginal candidosis. Lancet 369: 1961-1971.
24. Taylor BN, Staib P , Binder A, Biesemeier A, Sehnal M, Rö llinghoff M , et al . 2005 . Profi le of Candida albicans-secreted aspartic proteinase elicited during vaginal infection. Infection and Immunity 73: 1828-1835.
25. Tosun I, Aydin F , Kaklikkaya N, Erturk M . 2005. Induction of secretory aspartyl proteinase of Candida albicans by HIV-1 but not HSV-2 or some other microorganisms associated with vaginal environment . Mycopathologia 159: 213-218.
26. Tsang CSP , Chu FCS, Leung WK, Jin LJ , Samaranayake LP , Siu SC . 2007. Phospholipase, proteinase and haemolytic activities of Candida albicans isolated from oral cavities of patients with type 2 diabetes mellitus . Journal of Medical Microbiology 56: 1393-1398.
27. Yildirim Z, Kilic N, Kalkanci A . 2011. Fluorometric determination of acid proteinase activity in Candida albicans strains from diabetic patients with vulvovaginal candidiasis. Mycoses 54: e463-e467.
28. Watanabe T , Takano M , Murakami M , Tanaka H , Matsuhisa A , Nakao N , et al . 1999 . Characterization of a haemolytic factor from Candida albicans . Microbiology 145: 689-694.
29. Zhu W , Filler SG . 2010. Interactions of Candida albicans wiThepithelial cells . Cellular Microbiology 12: 273-282.